913346-12-0Relevant articles and documents
Development of a Practical Synthesis of the Progesterone Receptor Antagonist 4-{[3-Cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy}-2,6- dimethylbenzo-nitrile
Bradley, Paul A.,De Koning, Pieter D.,Johnson, Patrick S.,Lecouturier, Yann C.,McManus, David J.,Robin, Aurelie,Underwood, Toby J.
experimental part, p. 848 - 853 (2010/04/22)
The development and implementation of a scaleable process for the manufacture of the nonsteroidal progesterone receptor antagonist 8 is described. Key aspects of the synthesis include (i) a telescoped chlorination- etherification sequence to prepare diket
Compounds Useful In Therapy
-
Page/Page column 18-19, (2008/06/13)
Compounds of Formula (I): and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, are useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
